210
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Real-World Effectiveness and Safety of Apixaban versus Warfarin in Patients with Acute Venous Thromboembolism: Experience of a Large Tertiary Hospital in Saudi Arabia

ORCID Icon, ORCID Icon, , ORCID Icon, , , , , , , , ORCID Icon, ORCID Icon, ORCID Icon, , & ORCID Icon show all
Pages 4031-4037 | Published online: 28 Jul 2021

References

  • Mahan CE, Borrego ME, Woersching AL, et al. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost. 2012;108(08):291–302. doi:10.1160/TH12-03-0162
  • Stone J, Hangge P, Albadawi H, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther. 2017;7(Suppl 3):S276–S284. doi:10.21037/cdt.2017.09.01
  • Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738. doi:10.1182/bloodadvances.2020001830
  • Quante M, Thate-Waschke I, Schofer M. [What are the reasons for patient preference? A comparison between oral and subcutaneous administration]. Z Orthop Unfall. 2012;150(4):397–403. (German). doi:10.1055/s-0031-1298347
  • Wong A, Kraus PS, Lau BD, et al. Patient preferences regarding pharmacologic venous thromboembolism prophylaxis. J Hosp Med. 2015;10(2):108–111. doi:10.1002/jhm.2282
  • Bishop L, Young S, Twells L, Dillon C, Hawboldt J. Patients’ and physicians’ satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic. BMC Res Notes. 2015;8:233. doi:10.1186/s13104-015-1187-8
  • U.S. Food and Drug Administration (U.S. FDA). Pradaxa; 2010. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000TOC.cfm. Accessed April 20, 2021.
  • Julia S, James U. Direct oral anticoagulants: a quick guide. Eur Cardiol. 2017;12(1):40–45. doi:10.15420/ecr.2017:11:2
  • Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808. doi:10.1056/NEJMoa1302507
  • Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551–555. doi:10.1038/bjc.2013.725
  • Cullell N, Carrera C, Muiño E, Torres N, Krupinski J, Fernandez-Cadenas I. Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants. Oncotarget. 2018;9(49):29238–29258. doi:10.18632/oncotarget.25579
  • Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694. doi:10.1111/j.1538-7836.2005.01204.x
  • Griffin BA, McCaffrey DF, Burgette LF, et al. Coffman, State-of-the-Art Strategies for Addressing Selection Bias When Comparing Two or More Treatment Groups. Santa Monica, CA: RAND Corporation; 2020. Available from: https://www.rand.org/pubs/conf_proceedings/CF421.html.
  • Griffin BA, Sanchez R, Cefalu M, et al. Toolkit for Weighting and Analysis of Nonequivalent Groups: A Tutorial on the TWANG Shiny App for Two Treatments. Santa Monica, CA: RAND Corporation; 2020. Available from: https://www.rand.org/pubs/tools/TLA570-2.html.
  • Dawwas GK, Smith SM, Dietrich E, Lo-Ciganic W-H, Park H. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. Am J Health Syst Pharm. 2020;77(3):188–195. doi:10.1093/ajhp/zxz307
  • Weycker D, Li X, Wygant GD, et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice. Thromb Haemost. 2018;118(11):1951–1961. doi:10.1055/s-0038-1673689
  • Weycker D, Wygant GD, Guo JD, et al. Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses. Blood Adv. 2020;4(2):432–439. doi:10.1182/bloodadvances.2019001081
  • Al Ammari M, AlBalwi M, Sultana K, et al. The effect of the VKORC1 promoter variant on warfarin responsiveness in the Saudi WArfarin Pharmacogenetic (SWAP) cohort. Sci Rep. 2020;10(1):11613. doi:10.1038/s41598-020-68519-9
  • Ireland R. Warfarin bleeding risk increased in CKD. Nat Rev Nephrol. 2009;5(6):306. doi:10.1038/nrneph.2009.58
  • Hazlewood KA, Fugate SE, Harrison DL. Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother. 2006;40(12):2101–2106. doi:10.1345/aph.1H418
  • Anouassi Z, Atallah B, Alsoud LO, et al. Appropriateness of the direct oral anticoagulants dosing in the Middle East Gulf Region. J Cardiovasc Pharmacol. 2021;77(2):182–188. doi:10.1097/fjc.0000000000000913